This Article Full Text Full Text (PDF) Related Article Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Ofran, Y. Articles by Ritz, J. Search for Related Content PubMed PubMed Citation Articles by Ofran, Y. Articles by Ritz, J. Related Collections Key Article

Targets of Tumor Immunity After Allogeneic Hematopoietic Stem Cell Transplantation

Authors' Affiliation: Cancer Vaccine Center, Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts

Requests for reprints: Jerome Ritz, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115. Phone: 617-632-3465; Fax: 617-632-5167; E-mail: jerome_ritz{at}dfci.harvard.edu.

Abstract

The effectiveness of allogeneic hematopoietic stem cell transplantation for hematologic malignancies results from the donor immunity to antigens expressed in leukemia cells in the recipient. Similar immune responses have now been identified in patients with renal cell cancer with tumor regression after allogeneic hematopoietic stem cell transplantation. Further studies to identify relevant antigens and mechanisms of resistance may improve the effectiveness of this approach in patients with solid tumors.

Key Article

C19orf48 Encodes a Minor Histocompatibility Antigen Recognized by CD8⁺ Cytotoxic T Cells from Renal Cell Carcinoma Patients

Scott S. Tykodi, Nobuharu Fujii, Nathalie Vigneron, Sharon M. Lu, Jeffrey K. Mito, Maureen X. Miranda, Jeffrey Chou, Lilien N. Voong, John A. Thompson, Brenda M. Sandmaier, Peter Cresswell, Benoît Van den Eynde, Stanley R. Riddell, and Edus H. Warren
Clin. Cancer Res. 2008 14: 5260-5269. [Abstract] [Full Text] [PDF]